{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:21:15Z","timestamp":1777321275803,"version":"3.51.4"},"reference-count":33,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>For three decades, enzyme replacement therapy (ERT), and more recently, substrate reduction therapy, have been the standard-of-care for type I Gaucher disease (GD1). Since 2012, three different ERTs have been available. No clinical trial or academic study has ever compared these ERTs beyond one year. Herein we compare the impact of the ERTs on repeated measurements of glucosylsphingosine (lyso-Gb1; the most sensitive and GD-specific biomarker). A total of 135 adult patients (77 (57%) female) with GD1, followed from July 2014 to March 2020 and treated with a single ERT (imiglucerase (n = 41, 30.4%), taliglucerase alfa (n = 21, 15.6%) and velaglucerase alfa (n = 73, 54.1%)), were included. Disease severity was defined by genotypes (mild: N370S (c.1226A&gt;G) homozygous and N370S\/R496H (c.1604G) compound heterozygous; severe: all other genotypes) and by the severity score index (SSI; mild: &lt;7; severe: \u22657). Lyso-Gb1 testing was performed at Centogene\u2122 on dry blood spot samples collected during routine visits. Patients treated with imiglucerase had higher lyso-Gb1 levels at different time points. A huge variation in lyso-Gb1 levels was noticeable both inter-individually and intra-individually for all three ERTs. A steeper and faster decrease of lyso-Gb1 levels was shown in velaglucerase alfa. Nevertheless, the differences between medications were not very large, and bigger numbers and more pretreatment data are required for more powerful conclusions.<\/jats:p>","DOI":"10.3390\/ijms22147699","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T10:07:37Z","timestamp":1626689257000},"page":"7699","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1866-5644","authenticated-orcid":false,"given":"Tama","family":"Dinur","sequence":"first","affiliation":[{"name":"Shaare Zedek Medical Center, Gaucher Unit, Jerusalem 9103102, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Grittner","sequence":"additional","affiliation":[{"name":"Berlin Institute of Health, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 10117 Berlin, Germany"},{"name":"Institute of Biometry and Clinical Epidemiology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 10117 Berlin, Germany"},{"name":"Centogene AG, 18055 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9151-0337","authenticated-orcid":false,"given":"Shoshana","family":"Revel-Vilk","sequence":"additional","affiliation":[{"name":"Shaare Zedek Medical Center, Gaucher Unit, Jerusalem 9103102, Israel"},{"name":"Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112002, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Becker-Cohen","sequence":"additional","affiliation":[{"name":"Shaare Zedek Medical Center, Gaucher Unit, Jerusalem 9103102, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7598-2828","authenticated-orcid":false,"given":"Majdolen","family":"Istaiti","sequence":"additional","affiliation":[{"name":"Shaare Zedek Medical Center, Gaucher Unit, Jerusalem 9103102, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Cozma","sequence":"additional","affiliation":[{"name":"Centogene AG, 18055 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Rolfs","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of Rostock, 18051 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0077-8608","authenticated-orcid":false,"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[{"name":"Shaare Zedek Medical Center, Gaucher Unit, Jerusalem 9103102, Israel"},{"name":"Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112002, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"ref_1","unstructured":"Kaushansky, K., Lichtman, M., Prchal, J., Levi, M., Press, O., Burns, L., and Caligiuri, M. (2021). Gaucher disease and related lysosomal storage diseases. Williams Hematology, McGraw-Hill. [10th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/jama.298.11.1281","article-title":"Carrier screening for Gaucher disease: Lessons for low-penetrance, treatable diseases","volume":"298","author":"Zuckerman","year":"2007","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1002\/ajh.24063","article-title":"Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry","volume":"90","author":"Grabowski","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1002\/ajh.24057","article-title":"Gaucher disease and comorbidities: B-cell malignancy and parkinsonism","volume":"90","author":"Cox","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1006\/mgme.2001.3269","article-title":"Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: Implications for the prediction of disease severity","volume":"75","author":"Whitfield","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hurvitz, N., Dinur, T., Becker-Cohen, M., Cozma, C., Hovakimyan, M., Oppermann, S., Demuth, L., Rolfs, A., Abramov, A., and Zimran, A. (2019). Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20123033"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2021.01.002","article-title":"Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes","volume":"132","author":"Daykin","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjh.15402","article-title":"How we manage Gaucher Disease in the era of choices","volume":"182","author":"Szer","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","article-title":"Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe","volume":"37","author":"Belmatoug","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: Relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Rolfs, A., Giese, A.K., Grittner, U., Mascher, D., Elstein, D., Zimran, A., Bottcher, T., Lukas, J., Hubner, R., and Golnitz, U. (2013). Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079732"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Revel-Vilk, S., Fuller, M., and Zimran, A. (2020). Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197159"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1651-2227.2005.tb02110.x","article-title":"Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases","volume":"94","author":"Aerts","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Cozma, C., Cullufi, P., Kramp, G., Hovakimyan, M., Velmishi, V., Gjikopulli, A., Tomori, S., Fischer, S., Oppermann, S., and Grittner, U. (2020). Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134577"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"E140","DOI":"10.1002\/ajh.25074","article-title":"Glucosylsphingosine is a reliable response biomarker in Gaucher disease","volume":"93","author":"Arkadir","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Dinur, T., Zimran, A., Becker-Cohen, M., Arkadir, D., Cozma, C., Hovakimyan, M., Oppermann, S., Demuth, L., Rolfs, A., and Revel-Vilk, S. (2019). Long Term Follow-Up of 103 Untreated Adult Patients with Type 1 Gaucher Disease. J. Clin. Med., 8.","DOI":"10.3390\/jcm8101662"},{"key":"ref_17","first-page":"100567","article-title":"The N370S\/R496H genotype in type 1 Gaucher disease\u2014Natural history and implications for pre symptomatic diagnosis and counseling","volume":"22","author":"Zeid","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2005.09.007","article-title":"Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles","volume":"12","author":"Sawkar","year":"2005","journal-title":"Chem. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4155\/cli.10.21","article-title":"Velaglucerase alfa in the treatment of Gaucher disease type 1","volume":"1","author":"Burrow","year":"2011","journal-title":"Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/glycob\/cwp138","article-title":"Characterization of gene-activated human acid-beta-glucosidase: Crystal structure, glycan composition, and internalization into macrophages","volume":"20","author":"Brumshtein","year":"2010","journal-title":"Glycobiology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23381","article-title":"Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease","volume":"88","author":"Gonzalez","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_22","unstructured":"(2021, July 17). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022458s023lbl.pdf."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Shemesh, E., Deroma, L., Bembi, B., Deegan, P., Hollak, C., Weinreb, N.J., and Cox, T.M. (2015). Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database Syst. Rev., CD010324.","DOI":"10.1002\/14651858.CD010324.pub2"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bcmd.2016.10.012","article-title":"Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease","volume":"68","author":"Nascimbeni","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2017.08.005","article-title":"Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naive and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials","volume":"122","author":"Elstein","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(89)90536-9","article-title":"Prediction of severity of Gaucher\u2019s disease by identification of mutations at DNA level","volume":"2","author":"Zimran","year":"1989","journal-title":"Lancet"},{"key":"ref_27","unstructured":"IBM Corp (2019). IBM SPSS Statistics for Windows, IBM Corp.. Version 26.0."},{"key":"ref_28","unstructured":"R Core Team (2013). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: https:\/\/www.R-project.org\/."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting Linear Mixed-Effects Models Using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J. Stat. Softw."},{"key":"ref_30","unstructured":"Jaeger, B. (2021, July 17). r2glmm: Computes R Squared for Mixed (Multilevel) Models. R Package Version 0.1.2. Available online: https:\/\/CRAN.R-project.org\/package=r2glmm."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Wickham, H. (2016). ggplot2: Elegant Graphics for Data Analysis (Use R!), Springer.","DOI":"10.1007\/978-3-319-24277-4"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"772","DOI":"10.21105\/joss.00772","article-title":"ggeffects: Tidy data frames of marginal effects from regression models","volume":"3","year":"2018","journal-title":"J. Open Source Softw."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10897-017-0137-0","article-title":"Attitudes of Individuals with Gaucher Disease toward Substrate Reduction Therapies","volume":"27","author":"Wagner","year":"2018","journal-title":"J. Genet. Couns"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/14\/7699\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:31:45Z","timestamp":1760164305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/14\/7699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":33,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["ijms22147699"],"URL":"https:\/\/doi.org\/10.3390\/ijms22147699","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]}}}